Abzena secures $65m to expand production capacity, mammalian biologics site set to come online

By Jane Byrne contact

- Last updated on GMT

© GettyImages/simoncarter
© GettyImages/simoncarter

Related tags: CDMO, abzena, bioconjugates, Drug development, fill/finish

Abzena, a global CDMO specializing in the integrated development and manufacture of complex biologics and bioconjugates, has secured $65M in new funding.

The investment round was led by Welsh, Carson, Anderson & Stowe (WCAS) and Biospring Partners, among other investors.

The funding will allow Abzena to increase the capacity of its manufacturing capabilities for both clinical and commercial supply. “This new capital will allow us to develop and manufacture a greater number of novel treatments for more patients,"​ said Jonathan Goldman, CEO of Abzena.

In addition to building out existing and new manufacturing facilities, the contract development and manufacturing organization (CDMO) said the capital will boost its drug discovery and cell line service, as well as adding fill/finish capabilities and a new biological testing laboratory.

Abzena is opening a new manufacturing facility in Sanford, North Carolina this year – that site is expected to be online in Q4 - and it will be its sixth in a global network. The facility will be dedicated to cGMP manufacturing capacity for mammalian biologics, with it kitted out to support continuous manufacturing and perfusion. 

That capacity expansion move has been driven by an increase in customer demand for clinical and commercial scale 2,000L single use bioreactors across a wide range of therapeutic areas, said the organization. 

The goal of the Sanford site, according to a company announcement last year, is to provide integrated asset development with a full suite of in-house services from discovery through clinical and commercial phases without the need for technology transfer.

ADC partnership

In February this year, Abzena formed an ADC manufacturing partnership​ with BiVictriX Therapeutics plc, an emerging UK biotech.

The collaboration enables BiVictriX to cost-effectively manufacture its anti-cancer ADCs for use in pre-clinical models without the need for extensive manufacturing facilities of its own.

Tiffany Thorn, CEO of BiVictriX, commented: “Utilizing Abzena’s extensive knowledge in the field will be highly valuable as we look to expedite the development of our lead candidate, BVX001, and additional pipeline candidates towards achieving key pre-clinical milestones.”

Related news

Show more

Related products

show more

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us


View more